Scholars@Duke
Jyotsna Mullur

Selected Publications

Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization.

Journal Article Am J Rhinol Allergy · March 2025 BACKGROUND: Patients with aspirin-exacerbated respiratory disease (AERD) have difficult-to-treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and often require treatment with biologic therapy for asthma or CRSwNP. Healthcare utilization in ... Full text Link to item Cite

Dupilumab rapidly improves eustachian tube dysfunction and otologic symptoms in aspirin-exacerbated respiratory disease.

Journal Article Allergy Asthma Proc · November 1, 2024 Background: Patients with aspirin-exacerbated respiratory disease (AERD) frequently experience symptoms consistent with eustachian tube dysfunction (ETD), which can substantially impair patient quality of life. Methods: We analyzed a cohort of 98 adult pat ... Full text Link to item Cite

Validation of a questionnaire assessing smell loss in an international aspirin-exacerbated respiratory disease population.

Journal Article Allergy Asthma Proc · January 1, 2024 Background: Olfactory dysfunction (OD) and smell loss affects aspects of patients' everyday life and lowers their quality of life. OD questionnaires are considered one of the core-outcome measures in chronic rhinosinusitis, but many existing smell loss que ... Full text Link to item Cite

Aspirin-exacerbated respiratory disease: Updates in the era of biologics.

Journal Article Ann Allergy Asthma Immunol · September 2023 OBJECTIVE: Aspirin-exacerbated respiratory disease (AERD) is a chronic respiratory condition characterized by severe chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic asthma, and respiratory reactions to cyclooxygenase inhibitors. The managem ... Full text Link to item Cite

Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.

Journal Article Clin Exp Allergy · December 2022 BACKGROUND: The impact of anosmia on quality-of-life (QoL) for patients with aspirin-exacerbated respiratory disease (AERD) is poorly understood. We aimed to investigate how the severity of smell loss and olfactory dysfunction (OD) in patients with AERD af ... Full text Link to item Cite

Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.

Journal Article Ann Allergy Asthma Immunol · May 2022 BACKGROUND: Patterns of medication use and efficacy in aspirin-exacerbated respiratory disease (AERD) have not been well characterized, especially since the advent of respiratory biologics. Aspirin therapy after desensitization (ATAD) is efficacious for up ... Full text Link to item Cite

Ambulatory Virtual Care During a Pandemic: Patient Safety Considerations.

Journal Article J Patient Saf · March 1, 2022 BACKGROUND: The COVID-19 pandemic prompted sudden and fundamental changes in health care, including a rapid rise in the utilization of telehealth services in the ambulatory setting. With the unprecedented and significant decline in traditional office-based ... Full text Link to item Cite

The immunologic response to severe acute respiratory syndrome coronavirus 2.

Journal Article Allergy Asthma Proc · November 1, 2021 Background: The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated the worst global pandemic in a century, which has caused millions of infections and deaths as well as massive economic repercussions. Objective: As with ... Full text Link to item Cite

Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production.

Journal Article Cell · December 10, 2020 Antibodies are key immune effectors that confer protection against pathogenic threats. The nature and longevity of the antibody response to SARS-CoV-2 infection are not well defined. We charted longitudinal antibody responses to SARS-CoV-2 in 92 subjects a ... Full text Link to item Cite